New Jersey lawmakers push for Silver Alert notifications on mobile devices
Many of us are familiar with the notifications we get on our phones in the event of an Amber Alert—usually accompanied by a long, drawn-out audio and haptic notification. Lawmakers here envision the same thing for Silver Alerts.
More Local News
'That individual needs our help immediately,' said Assemblywoman Annette Quijano (D-NJ 20th District). 'Not two days later, but immediately… We must protect all our members of our families – young and old.'
A Silver Alert goes out in the event of a missing person who is believed to be suffering from Alzheimer's disease, dementia, or other cognitive impairment, regardless of age, and is believed to be in danger.
Silver Alerts are often seen on highway message boards and on social media, but aren't automatically sent to the masses like Amber Alerts. New legislation from Quijano looks to change that.
'As we all age and our parents are aging, I think individuals are now grappling with 'what do you do?' and this is one answer to that question,' said Quijano.
Republican Assemblyman Antwan McClellan voted to advance the bill in Thursday's Public Safety and Preparedness Committee.
'Time is crucial so you never know — especially if somebody has dementia — if it's cold, you don't know how they left the house and what elements they're walking into,' said McClellan (R-NJ 1st District). 'We want to make sure that we get to them before they cause any physical harm to themselves.'
'Within the first 24 hours statistically, most people are found safely,' said Ken Zaentz, President and CEO of Alzheimer's New Jersey. 'But in the second 24 hours, about 50 percent of those who have wandered, when they are found, they've succumbed.'
Zaentz says at least 60 percent of people with Alzheimer's will wander at some point, oftentimes out of confusion, frustration, or fear.
'Maybe they're looking for a place that was familiar, like a place they used to live,' said Zaentz, 'or if they worked nearby they could be traveling towards that workplace.'
The bill advanced through the committee on Thursday.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Crinetics Pharmaceuticals, Inc. (CRNX)' Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data
We recently compiled a list of Crinetics Pharmaceuticals, Inc. stands fifth on our list. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands fifth on our list among the best future growth stocks to buy now. It is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies for rare endocrine diseases and tumors. Its lead candidate, PALSONIFY (paltusotine), is an investigational once-daily oral somatostatin receptor type 2 (SST2) agonist being developed for acromegaly. At the July 2025 ENDO Annual Meeting, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) presented long-term data from the open-label extensions of its PATHFNDR-1 and PATHFNDR-2 Phase 3 trials, showing that PALSONIFY maintained durable IGF-1 control, reduced symptom burden, and had a consistent safety profile. These findings strengthen its case as a next-generation oral alternative to current injectable therapies, which are the standard of care for acromegaly. The company is now approaching a major inflection point, with a PDUFA date set for late 2025, potentially making PALSONIFY the first oral treatment approved for acromegaly. This would represent a significant shift in disease management and convenience for patients. A scientist in a laboratory looking into a microscope, researching advances in biopharmaceuticals for central nervous system disorders. Beyond PALSONIFY, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is advancing other pipeline programs, including Atumelnant, aimed at treating congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, as well as several early-stage endocrine disorder therapies. The corporation also expanded its workforce in July 2025, granting equity awards to 46 new employees to support future growth. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Scientists Find 2 Existing Drugs Can Reverse Alzheimer's Brain Damage in Mice
In efforts to beat Alzheimer's disease, researchers are looking at existing drugs that could tackle the condition, and a new study identifies two promising candidates that are currently used to treat cancer. Already approved by regulators in the US – meaning potential clinical trials for Alzheimer's could start sooner – the drugs are letrozole (usually used to treat breast cancer) and irinotecan (usually used to treat colon and lung cancer). Researchers from the University of California, San Francisco (UCSF) and Gladstone Institutes started by looking at how Alzheimer's altered gene expression in the brain. They then consulted a medical database called the Connectivity Map to look for drugs that reversed these gene expression changes, and cross-referenced records of patients who had taken these drugs as part of cancer treatments and their likelihood of developing Alzheimer's. Intriguingly, the drugs seemed to have reduced their risk. Related: "Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly," says computational biologist Marina Sirota, from UCSF. "We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications." Having picked out letrozole and irinotecan as the best candidates, the researchers tested them in mouse models of Alzheimer's. When used in tandem, the drugs were shown to reverse some of the brain changes brought on by the disease. The harmful clumps of tau protein that build up in brains affected by Alzheimer's were reduced significantly, and the mice showed improvements in learning and memory tasks – two brain capabilities often impaired by Alzheimer's. By combining the two drugs together, the researchers were able to target different types of brain cells affected by the disease. Letorozole seemed to counter Alzheimer's in neurons, while irinotecan worked in glia. "Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health," says neuroscientist Yadong Huang, from UCSF and Gladstone. "This makes it very challenging for drug development – which traditionally produces one drug for a single gene or protein that drives disease." It's a promising start, but there's more work to be done: obviously the drugs have only been directly tested in mice so far, and these medications also come with side effects attached. They need to be reconsidered if the drugs are going to be repurposed for a different disease than what they were originally approved for. One of the next steps should be clinical trials for people with Alzheimer's disease. According to the researchers, this approach could lead to more personalized and effective treatments, based on how gene expression has been altered in each case. It's estimated that more than 55 million people have Alzheimer's today, and as the world's population ages, that's expected to more than double in the next 25 years. Finding ways to prevent the disease and even reverse symptoms would have a huge impact on global health. "If completely independent data sources, such as single-cell expression data and clinical records, guide us to the same pathways and the same drugs, and then resolve Alzheimer's in a genetic model, then maybe we're on to something," says Sirota. "We're hopeful this can be swiftly translated into a real solution for millions of patients with Alzheimer's." The research has been published in Cell. Related News Psilocybin Extends Life of Human Cells by 50% in Wild New Study Celebrity Undergoes Controversial Procedure to Clean Blood of Microplastics COVID Can Cause Alzheimer's-Like Plaques in Eyes And Brain Solve the daily Crossword
Yahoo
4 hours ago
- Yahoo
Sleepiness Could Be Triggered by a Power Overload in Our Brain
Denied of sleep, we find it but impossible to keep our eyes open and our thoughts focused. A new study based on fruit flies may have pin-pointed the origins of this biological lullaby, and with it a deeper understanding of our need for rest on a cellular level. Researchers from the University of Oxford in the UK have identified our cell's mitochondria as responsible for signaling when the body has to get some shut-eye as soon as possible. These tiny power generators cause a kind of metabolic overload in sleep-regulating neurons, the researchers suggest, which in simple terms indicates when our brain is running on empty. Through sleep, this overload can be reset, ensuring the brain remains in a healthy state. Related: "We set out to understand what sleep is for, and why we feel the need to sleep at all," says physiologist Gero Miesenböck. "Despite decades of research, no one had identified a clear physical trigger." "Our findings show that the answer may lie in the very process that fuels our bodies: aerobic metabolism." The team studied neurons responsible for regulating sleep in fruit flies, which have enough biological similarities to humans to make them useful for research. Through a comparison of well-rested and sleep-deprived fruit flies, the researchers identified differences in gene activity and electrical signaling. Overloaded mitochondria in sleep-deprived brains were found to shed electrons, increasing the generation of harmful waste products. The sleep-regulating neurons respond to these molecules by going into overdrive, making sleep a top biological priority. "You don't want your mitochondria to leak too many electrons," says neuroscientist Raffaele Sarnataro. "When they do, they generate reactive molecules that damage cells." Genetically engineering flies with a higher production of electrons in their sleep-regulating cells resulted in fruit flies that also slept more. Similarly, flies with a reduced level of electron generation slept less. There are, of course, other pressures on sleep, from how many coffees you have per day to the alignment of your circadian rhythm – the internal schedule that tells your body when it's time for bed. But now we have an actual cellular mechanism controlling sleep, and showing why we can't do without it. Anything new we learn about sleep can inform the treatment of sleep disorders and even neurological conditions such as Alzheimer's. These diseases are closely linked to sleep and the way it protects the brain, and connections to mitochondria could be something for future studies to investigate. The study also joins some of the dots between metabolism, sleep, and lifespan. Smaller animals tend to sleep more and live shorter lives, and the activity of mitochondria – and the waste that needs clearing up – could be part of the reason why. "This research answers one of biology's big mysteries," says Sarnataro. "Why do we need sleep? The answer appears to be written into the very way our cells convert oxygen into energy." The research has been published in Nature. Related News Study Reveals Key Way to Slow Chronic Illness in Old Age Liver Cancer Predicted to Double by 2050, But There Is Hope One Weekend Habit May Cut Risk of Heart-Related Death by 33%, Study Finds Solve the daily Crossword
